1359669-62-7

Basic information

• Product Name: diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate
• Synonyms: diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate
• CAS NO: 1359669-62-7
• Molecular Weight: 487.596
• Mol File: 1359669-62-7.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate(CAS DataBase Reference)
• NIST Chemistry Reference: diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate(1359669-62-7)
• EPA Substance Registry System: diethyl {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}malonate(1359669-62-7)

Safety Data

• Hazardous Substances Data: 1359669-62-7(Hazardous Substances Data)

Upstream product

• 31163-13-0 ethyl 2-(bromomethyl)-6-chloronicotinate 
• 3424-43-9 ethyl 2-methyl-6-oxo-1,6-dihydropyridine-3-carboxylate 
• 31163-14-1 diethyl 2-((6-chloro-3-(ethoxycarbonyl)pyridin-2-yl)methyl)-malonate 
• 100379-00-8 2,6-dimethylbenzene boronic acid 
• 53256-25-0 (2E,4Z)-5-ethyl 1-methyl 4-(1-aminoethylidene)pent-2-enedioate 
• 41598-57-6 ethyl 2-chloro-5-oxo-6,7-dihydro-5H-cyclopenta[b]pyridine-6-carboxylate 
• 3132-99-8 m-bromobenzoic aldehyde 
• 1359668-78-2 2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-ol 
• 105-53-3 diethyl malonate 
• 1359669-60-5 C₂₃H₂₁NO₂ 
• 691905-27-8 (2',6'-dimethyl-[1,1'-biphenyl]-3-yl)methanol 
• 691905-26-7 2',6'-dimethyl-[1,1'-biphenyl]-3-carbaldehyde 

Downstream Products

• 1359668-80-6 {2-[(2',6'-dimethylbiphenyl-3-yl)methoxy]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-yl}acetic acid 

Relevant articles and documents

Identification of fused-ring alkanoic acids with improved pharmacokinetic profiles that Act as G protein-coupled receptor 40/free fatty acid receptor 1 agonists

The G protein-coupled receptor 40 (GPR40)/free fatty acid receptor 1 (FFA1) has emerged as an attractive target for a novel insulin secretagogue with glucose dependency. We previously identified phenylpropanoic acid derivative 1 (3-{4-[(2′,6′-dimethylbiphenyl-3-yl)methoxy]-2-fluorophenyl} propanoic acid) as a potent and orally available GPR40/FFA1 agonist; however, 1 exhibited high clearance and low oral bioavailability, which was likely due to its susceptibility to β-oxidation at the phenylpropanoic acid moiety. To identify long-acting compounds, we attempted to block the metabolically labile sites at the phenylpropanoic acid moiety by introducing a fused-ring structure. Various fused-ring alkanoic acids with potent GPR40/FFA1 activities and good PK profiles were produced. Further optimizations of the lipophilic portion and the acidic moiety led to the discovery of dihydrobenzofuran derivative 53 ((6-{[4′-(2-ethoxyethoxy)-2′,6′-dimethylbiphenyl-3-yl]methoxy} -2,3-dihydro-1-benzofuran-3-yl)acetic acid), which acted as a GPR40/FFA1 agonist with in vivo efficacy during an oral glucose tolerance test (OGTT) in rats with impaired glucose tolerance.